• ACCENT trial in pancreatic cancer completed recruitment ahead of schedule
• Interim data shows 13 patients achieved confirmed partial responses
• Significant progress made in initiating FOLFIRINOX trial

Amplia Therapeutics Limited (ASX: ATX) has announced further progress across its small molecule, focal adhesion kinase (FAK) inhibitor program and the release of its Appendix 4C Cash Flow Report for the quarter ending 31 March 2025. Key highlights include the completion of recruitment for the Phase 2a ACCENT trial, investigating narmafotinib with standard chemotherapy for advanced pancreatic cancer, which was completed two months ahead of schedule. The company reported that a total of 13 patients had recorded confirmed partial responses, suggesting the narmafotinib combination may be more effective than chemotherapy alone. Significant progress has also been made in initiating a second trial in the US and Australia, combining narmafotinib with FOLFIRINOX, with the FDA providing positive feedback on modifications to the trial protocol. The company will continue to focus on the execution of the ACCENT trial and progress activities supporting the initiation of the FOLFIRINOX trial, with the aim to have the first patient dosed before the end of the quarter.

The company will continue to focus on execution of the Phase 2a ACCENT trial and will report key trial data to the market as it becomes available. Activities supporting initiation of the US trial of narmafotinib in combination with FOLFIRINOX will also continue to be progressed with the aim to have the first patient dosed before the end of the quarter.